Literature DB >> 20556802

Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction.

Domenic Sica1, Ron M Oren, Mildred D Gottwald, Roger M Mills.   

Abstract

BACKGROUND: In patients with heart failure, few data describe the neurohormonal response to nesiritide and furosemide either alone or in combination. This study systematically compared the effects of nesiritide, furosemide, and their combination on natriuresis/diuresis and plasma aldosterone in patients with chronic stable heart failure who were relatively diuretic resistant. HYPOTHESIS: Natriuretic, diuretic, and neurohormonal responses to furosemide and nesiritide will differ when these agents are administered alone vs. in combination.
METHODS: Twenty-eight subjects completed a multicenter, open-label, three-arm crossover study. Each subject received the following treatments in random order on alternate days: (1) furosemide, 40 mg intravenous bolus; (2) nesiritide, 2 microg/kg intravenous bolus followed by a 0.01 microg/kg/min infusion for 6 hours; (3) both furosemide and nesiritide, with furosemide given at least 15 minutes after initiation of nesiritide.
RESULTS: Plasma aldosterone increased by 2.2 +/- 1.6 ng/dL after furosemide alone, decreased by 3.9 +/- 1.6 ng/dL after nesiritide alone (P = 0.005 vs furosemide alone and P = 0.56 vs furosemide plus nesiritide), and decreased by 2.8 +/- 1.6 ng/dL after furosemide plus nesiritide (P = 0.02 vs furosemide alone).
CONCLUSIONS: Furosemide alone produced natriuresis/diuresis and a prompt rise in plasma aldosterone values. Nesiritide alone produced no significant natriuresis/diuresis, but decreased plasma aldosterone values. When furosemide was administered on a background of nesiritide infusion, the observed natriuresis/diuresis was similar to that seen with furosemide alone, without the anticipated increase in plasma aldosterone observed with furosemide alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556802      PMCID: PMC6653257          DOI: 10.1002/clc.20787

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  2 in total

1.  Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial.

Authors:  Hiroyuki Nishi; Koichi Toda; Shigeru Miyagawa; Yasushi Yoshikawa; Satsuki Fukushima; Masashi Kawamura; Daisuke Yoshioka; Tetsuya Saito; Takayoshi Ueno; Toru Kuratani; Yoshiki Sawa
Journal:  Surg Today       Date:  2015-09-28       Impact factor: 2.549

2.  Enteral Sodium Chloride Supplementation and Fluid Balance in Children Receiving Diuretics.

Authors:  Laura Ortmann; Teri J Mauch; Jean Ballweg
Journal:  Children (Basel)       Date:  2022-01-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.